BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Investing.com - Mizuho reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma stock (NASDAQ:BBIO) ahead of a patent trial involving Pfizer’s tafamidis. The stock currently trades ...

A concept presented by NASA March 24 calls for the agency to procure a module attached to the ISS that could serve as the core of a commercial station. Credit: NASA WASHINGTON — NASA, concerned about ...

His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...

Commercial breaks often give TV viewers time for a trip to the bathroom — but never quite like this. In a 30-second ad that aired during NBC’s telecast of Super Bowl LX, Liquid I.V., a maker of ...